BeiGene's Btk inhibitor gets U.S. breakthrough designation
In: M2 Presswire, 2019-01-15
Zeitungsartikel
Zugriff:
BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said FDA granted breakthrough therapy designation to zanubrutinib (BGB-3111) to treat second-line mantle cell lymphoma (MCL). BeiGene President and General Manager of China Xiaobing Wu told [...]
Titel: |
BeiGene's Btk inhibitor gets U.S. breakthrough designation
|
---|---|
Zeitschrift: | M2 Presswire, 2019-01-15 |
Veröffentlichung: | 2019 |
Medientyp: | Zeitungsartikel |
Schlagwort: |
|
Sonstiges: |
|